Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Blood (2023) 142 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2023-178009

Published: 2023

Journal Articles

Concurrent Testing of Spatially Separated Tissue Samples and Circulating Tumor DNA Reveals Substantial Intra-Patient Genetic Heterogeneity in Relapsed/Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 171.

https://doi.org/10.1182/blood-2023-187554

Published: 2023

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes

Laurent Garderet, Mohammad Al Hariri, Joanna Wasielica-Poslednik, Markus Munder, Kitti Kormányos, Camila Peña, Alessandro Gozzetti, Xiang Zhou, Anna Waszczuk-Gajda, Laura Rosinol, Gabor Mikala, Mateusz Krzystanski, Walter Lisch, David H. Vesole, Nora Szentmáry, Artur Jurczyszyn

Blood (2021) 138 (Supplement 1): 2695.

https://doi.org/10.1182/blood-2021-151460

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

PORT (OP-109): Phase 2, Randomized, Pharmacokinetic (PK), Cross-over Study of Peripheral Vs Central Intravenous Administration of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Jiri Minarik, Ilina Micheva, Ganna Usenko, Gabor Mikala, Kameliya Simeonova, Marcus Thuresson, Markus Jerling, Hanjing Xie, Ludek Pour

Blood (2021) 138 (Supplement 1): 4772.

https://doi.org/10.1182/blood-2021-150639

Published: 2021

Journal Articles

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Virág Réka Szita, MD, Gábor Mikala, MD PhD, János Fábián, MD, Péter Rajnics, MD PhD, László Rejtő, MD PhD, Tamás Szendrei, MD, Hussain Alizadeh, MD PhD DSc, Laszlo Varoczy, MD PhD, Árpád Illés, MD PhD, Tamas Masszi, MD PhD, Gergely Varga, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139870

Published: 2020

Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1888.

https://doi.org/10.1182/blood-2019-126015

Published: 2019

Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Blood (2018) 132 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2018-99-115039

Published: 2018

Journal Articles

Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients

Blood (2018) 132 (Supplement 1): 2004.

https://doi.org/10.1182/blood-2018-99-112750

Published: 2018

Journal Articles

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, MD PhD, Zsolt Nagy, MD PhD, Szabolcs Kosztolányi, MD, Árpád Szomor, MD PhD, Tamás Schneider, MD PhD, Beáta Deák, MD PhD, Krisztina Wolf, MD, Márk Plander, MD PhD, Tamás Szendrei, MD, László Váróczy, MD PhD, Árpád Illés, MD PhD, Árpád Bátai, MD, Mónika Pető, MD, János Fábián, MD, Tamas Masszi, MD PhD, Gabor Mikala, MD PhD

Blood (2017) 130 (Supplement 1): 1865.

https://doi.org/10.1182/blood.V130.Suppl_1.1865.1865

Published: 2017

Journal Articles

The Effect of Proteasome Subunit Beta Type 1 P11A Polymorphism on the Survival of Multiple Myeloma Patients Treated with First Line Bortezomib Based Chemotherapy

Gergely Varga, MD, Gabor Mikala, MD PhD, Gergely Szombath, MD, Katalin Balassa, MD, Katalin Piroska Kiss, MD, Attila Tordai, PhD DSc, Hajnalka Andrikovics, MD PhD, Tamas Masszi, MD PhD

Blood (2015) 126 (23): 1765.

https://doi.org/10.1182/blood.V126.23.1765.1765

Published: 2015

Journal Articles

Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide

Florent Malard, Nicolaus Kröger, Ian H Gabriel, Dr, Kai Hübel, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Grzegorz Basak, MD, PhD, Kenneth W Douglas, MD, Catarina Geraldes, MD, Ozren Jaksic, MD, PhD, Zdenek Koristek, MD, PhD, Francesco Lanza, MD, Roberto M. Lemoli, MD, Gabor Mikala, MD, PhD, Dominik Selleslag, MD, Nina Worel, MD, Rafael F. Duarte, MD, PhD, Mohamad Mohty

Blood (2011) 118 (21): 1932.

https://doi.org/10.1182/blood.V118.21.1932.1932

Published: 2011

Journal Articles

Stem Cell Mobilization in Poor Mobilizers Using Plerixafor and G-CSF with or without Chemotherapy: A European Perspective

Maximilian M Fresen, MD, Rafael F. Duarte, MD, PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Grzegorz Basak, MD, PhD, Kenneth W Douglas, MD, Ian H Gabriel, MD, Catarina Geraldes, MD, Ozren Jaksic, MD, PhD, Zdenek Koristek, MD, PhD, Nicolaus Kröger, Francesco Lanza, MD, Roberto M. Lemoli, MD, Gabor Mikala, MD, PhD, Dominik Selleslag, MD, Nina Worel, MD, Florian Lange, Mohamad Mohty, Kai Hübel, MD

Blood (2011) 118 (21): 2993.

https://doi.org/10.1182/blood.V118.21.2993.2993

Published: 2011

Journal Articles

HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for JAK2 V617F Positive Chronic Myeloproliferative Disease.

Hajnalka Andrikovics, MD, PhD, Nora Meggyesi, Aniko Szilvasi, Julia Tamaska, MD, Gabriella Halm, MD, Sandor Lueff, MD, Sarolta Nahajevszky, MD, Miklos Egyed, MD, PhD, Judit Varkonyi, MD, PhD, Gabor Mikala, MD, PhD, Andrea Sipos, MD, Attila Tordai, MD, PhD, Tamas Masszi, MD, PhD

Blood (2006) 108 (11): 4904.

https://doi.org/10.1182/blood.V108.11.4904.4904

Published: 2006

Journal Articles

Striking Coincidence of IgD M-Protein and Translocation t(11;14) in Hungarian Myeloma Patients.

Gabor Mikala, MD, PhD, Emma Adam, Andras Kozma, Balazs Kapas, MD, Sarolta Nahajevszky, MD, Tamas Masszi, MD, PhD

Blood (2006) 108 (11): 5046.

https://doi.org/10.1182/blood.V108.11.5046.5046

Published: 2006

Journal Articles

Effective Treatment of Basophilic Leukemia of the Central Nervous System in a CML Patient with the Combination of Imatinib Mesylate and Valproic Acid.

Sarolta Nahajevszky, MD, Maria Magocsi, PhD, Gabor Mikala, PhD, Hajnalka Andrikovics, PhD, Emma Adam, Tamas Masszi, PhD

Blood (2005) 106 (11): 4886.

https://doi.org/10.1182/blood.V106.11.4886.4886

Published: 2005

NARROW

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Concurrent Testing of Spatially Separated Tissue Samples and Circulating Tumor DNA Reveals Substantial Intra-Patient Genetic Heterogeneity in Relapsed/Refractory Follicular Lymphoma

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

PORT (OP-109): Phase 2, Randomized, Pharmacokinetic (PK), Cross-over Study of Peripheral Vs Central Intravenous Administration of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

The Effect of Proteasome Subunit Beta Type 1 P11A Polymorphism on the Survival of Multiple Myeloma Patients Treated with First Line Bortezomib Based Chemotherapy

Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide

Stem Cell Mobilization in Poor Mobilizers Using Plerixafor and G-CSF with or without Chemotherapy: A European Perspective

HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for JAK2 V617F Positive Chronic Myeloproliferative Disease.

Striking Coincidence of IgD M-Protein and Translocation t(11;14) in Hungarian Myeloma Patients.

Effective Treatment of Basophilic Leukemia of the Central Nervous System in a CML Patient with the Combination of Imatinib Mesylate and Valproic Acid.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only